印度尼西亚万隆真实世界回顾性队列中儿童结核性脑膜炎的治疗结局
该研究回顾性评估了2011-2020年印度尼西亚万隆Hasan Sadikin医院283例儿童结核性脑膜炎患者的临床特征与结局。院内死亡44例(15.5%),出院后死亡18例(6.4%),治疗完成时91例(32.1%)存活者中33例(36.3%)有严重神经后遗症,118例(41.7%)结局未知。尽管接受治疗,儿童结核性脑膜炎仍导致大量神经后遗症和死亡,凸显改进早期诊断、结核预防和优化管理策略的重要性。
要点
- 283例中226例(79.9%)为II或III期结核性脑膜炎,153例(54.1%)年龄<5岁。
- 院内死亡44例(15.5%),预测因素包括III期、脑积水、男性、低收入父母、入院惊厥、未接种卡介苗。
- 治疗完成时91例(32.1%)存活,其中33例(36.3%)有严重神经后遗症。
核心结论
- 尽管接受治疗,印度尼西亚儿童结核性脑膜炎仍导致大量神经后遗症和死亡,凸显改进早期诊断、结核预防和优化管理策略的重要性。
研究设计与样本
- 回顾性评估2011-2020年印度尼西亚万隆Hasan Sadikin医院接受治疗的儿童结核性脑膜炎患者的临床特征和结局,共283例。
主要发现
- 283例中153例(54.1%)年龄<5岁,226例(79.9%)为II或III期结核性脑膜炎。
- 院内死亡44例(15.5%),预测因素为III期结核性脑膜炎、脑积水、男性、低收入父母、入院惊厥和未接种卡介苗。
- 出院后死亡18例(6.4%),预测因素为脑积水、结核瘤和未接种卡介苗。
- 治疗完成时91例(32.1%)记录为存活,其中33例(36.3%)有严重神经后遗症,118例(41.7%)结局未知。
- 严重神经后遗症的预测因素为基线体温>38°C、III期结核性脑膜炎和基线运动缺陷。
局限性
- 118例(41.7%)结局未知。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We retrospectively evaluated clinical features and outcomes in children treated for tuberculous meningitis (TBM) at Hasan Sadikin Hospital, Bandung, Indonesia, during 2011-2020. Among 283 patients, 153 (54.1%) were <5 years of age, and 226 (79.9%) had stage II or III TBM. Predictors of in-hospital death (n = 44 [15.5%]) were stage III TBM, hydrocephalus, male sex, low-income parents, seizures at admission, and lack of bacillus Calmette-Guérin vaccination. Predictors of postdischarge death (n = 18 [6.4%]) were hydrocephalus, tuberculoma, and lack of bacillus Calmette-Guérin vaccination. At treatment completion, 91 (32.1%) patients were documented to have survived, of whom 33 (36.3%) had severe neurologic sequelae and 118 (41.7%) had unknown outcomes. Predictors of severe neurologic sequelae were baseline temperature >38°C, stage III TBM, and baseline motor deficit. Despite treatment, childhood TBM in Indonesia causes substantial neurologic sequelae and death, highlighting the importance of improved early diagnosis, better tuberculosis prevention, and optimized TBM management strategies.
引用
- Nataprawira HM, Gafar F, Risan NA, et al. Treatment Outcomes of Childhood Tuberculous Meningitis in a Real-World Retrospective Cohort, Bandung, Indonesia. Emerg Infect Dis. 2022. PMID: 35202524. doi:10.3201/eid2803.212230
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。